Company
Building Europe's manufacturing network for radiopharmaceutical therapies
About Protherium
Why a dedicated industrial platform?
Multiple assets are now moving from early-stage clinical development to late-stage and commercial. Yet broad adoption of the most promising nuclear medicine drugs has been held back, in large part, by isotope supply and industrial capacity.
Many of the radiopharmaceuticals expected to reach the market in the coming years are developed outside Europe, by companies now seeking reliable production within Europe. Dedicated capacity for late-stage and commercial volumes remains limited.
Protherium offers a genuinely new alternative: independent production units backed by a team that fully integrates regulatory requirements, staffing needs, production and logistics operations.
Our mission
Expand radiopharmaceutical production capacity in Europe
To build the industrial infrastructure that expands radiopharmaceutical production capacity across Europe, and to offer radiopharmaceutical companies novel manufacturing solutions, from late-stage trials to commercial supply.
Our vision
Breakthrough therapies, widely available
To make breakthrough radiopharmaceutical therapies widely available across Europe, so that more and more patients can benefit from them, faster.
Nancy, France · Discover the site →
United Kingdom · Future site
Belgium · Future site
Germany · Future site
Switzerland · Future site
Sweden · Future site
Spain · Future site
Turkey · Future site
Nancy, FranceFirst production site
Future sitesUnited Kingdom · Belgium · Germany · Switzerland · Sweden · Spain · Turkey
European network
A model designed to be deployed across Europe
The market will need more than 30 dedicated radiopharmaceutical production sites by 2035.
Building on its Nancy site, Protherium plans to replicate its industrial model across Europe, drawing on in-house engineering expertise to design, build and commission each new facility.
Our model
A new model for radiopharmaceutical production
Each Protherium site hosts up to six ready-to-use production units, designed, built and commissioned by Protherium as self-contained facilities (hot cells, radiation shielding, processes adapted from beta to alpha emitters). Our first 7,100 m² platform is under construction in Gondreville, near Nancy, with its first two units available in April 2027.
Our first site, Nancy →
© Archi 3A
- Protherium unitOur own unit for CMO/CDMO services, R&D and clinical production.
- Dedicated Client UnitsReady-to-use production units dedicated to the large-scale manufacturing of your radiopharmaceuticals.
- Radionuclide supplySecure access to the radionuclides your product needs.
- Shared site servicesEngineering, staff, regulatory affairs and logistics, pooled across all units.
Team
The leadership team
Gilles Karcher
Co-founder and Chairman
An engineer from Supélec and a nuclear medicine physician, Gilles Karcher is Professor and former Head of the Nuclear Medicine Department at Nancy University Hospital (CHRU). He has played a central role in the development of nuclear medicine in France, notably as President of the French Society of Nuclear Medicine and of the National Council of Universities.
Richard Zimmermann
Co-founder
Richard Zimmermann has contributed to the creation of pioneering companies such as Telix Pharmaceuticals, Global Morpho Pharma, MEDraysintell and the Oncidium Foundation. His R&D expertise and in-depth knowledge of the global nuclear medicine industry are key assets for the strategy and international reach of Nancyclotep and Protherium.
Jean-Bernard Deloye
Co-founder and CEO
With 30 years of experience in hospital and industrial settings, Jean-Bernard Deloye has co-founded several companies specialising in short-lived radiopharmaceuticals, including Cyclopharma. CEO of Zionexa (GE HealthCare) since 2021, he served ten years on the board of LEEM and chairs the French Association of Nuclear Medicine Industries.
Nicolas Loniewski
Commercial Director
With over ten years in radiopharmaceuticals, Nicolas Loniewski has worked at Cyclopharma, Zionexa and GE HealthCare, where he built theranostic partnerships with pharma and biotech companies conducting trials in oncology, neurology and cardiology, and led a breast oncology programme through NDA filing and FDA approval. He began his career in M&A and corporate finance at Bryan Garnier & Co, Amundi and Société Générale.
Corinne Sulger
Regulatory Affairs Director
With nearly 30 years in pharmaceutical regulatory affairs, Corinne Sulger was Regulatory Affairs Manager at Zionexa. She previously spent almost 14 years at MSD France, where she managed product registrations in the diabetes and cardiometabolic areas before becoming QA Manager. Earlier, she was Regulatory Affairs Deputy Director for generic medicines at Laboratoires G GAM and a regulatory specialist at Besins International.
Atekka Chabanse
Radiopharmacy Consultant
A hospital pharmacist and radiopharmacist at the Mulhouse and Sud Alsace hospital group since 2006, Atekka Chabanse is responsible for the purchase of raw materials and for the production and quality control of radiopharmaceuticals, and acts as radiation protection advisor. Trained in Lyon and at INSTN in radiopharmacy, radiobiology and nuclear medicine, she also works as an independent radiopharmacy and radiation protection consultant and is an ambassador of the Oncidium Foundation.
Looking for production capacity in Europe?
Discover how Protherium supports your project, from process transfer to commercial production.
